Key Takeaways
- • CVC Capital Partners and Groupe Bruxelles Lambert have launched a €10.7 billion voluntary cash tender offer to take Italian pharmaceutical group Recordati private at €51.29 per share (€52.00 cum-dividend), representing a 12.89% premium to the undisturbed share price as of March 25, 2026.
- • CVC, which already controls 46.8% of Recordati through its Rossini holding company, has irrevocably committed to tender its shares, while GBL is deploying up to €1.3 billion to secure a co-control position alongside co-investors including the Abu Dhabi Investment Authority, Canada Pension Plan Investment Board, and chairman Andrea Recordati.
- • The transaction, valued at approximately $12.4 billion and representing 2026's largest European buyout to date, targets completion in the fourth quarter of 2026 and requires regulatory clearance and a minimum 66.67% acceptance threshold.
- • The consortium's strategic rationale centers on executing Recordati's rare disease platform growth strategy without public market constraints, citing the company's aggressive acquisition pace (16 acquisitions since 2018) and need for sustained R&D investment that would create quarterly earnings volatility in a listed structure.
Summary
CVC Capital Partners and Groupe Bruxelles Lambert have jointly launched a €10.7 billion cash tender offer to acquire Recordati, Italy's prominent pharmaceutical group, and delist it from Milan's stock exchange. The offer values each share at €51.29, or €52.00 including dividends, reflecting a 12.89% premium to Recordati's undisturbed trading price prior to the takeover announcement. The transaction, executed through acquisition vehicle Respighi BidCo, constitutes the largest European private equity buyout of 2026 to date, valued at approximately $12.4 billion.
CVC's involvement dates to 2018 and has grown substantially; the firm currently holds 46.8% of Recordati through its Rossini holding company and has irrevocably committed to tender its existing stake. Groupe Bruxelles Lambert is committing up to €1.3 billion to secure a co-control position, establishing itself as the transaction's co-lead alongside CVC. The consortium has secured commitments from institutional co-investors including the Abu Dhabi Investment Authority, Canada Pension Plan Investment Board, and Recordati's chairman Andrea Recordati, signaling broad institutional backing for the privatization.
The strategic rationale reflects a significant operational shift driven by Recordati's expansion trajectory. Since 2018, the company has completed sixteen acquisitions while building its rare disease platform—a competitive, capital-intensive segment requiring sustained research and development spending and access to early-stage assets. The sponsors argue that executing this strategy as a public company introduces execution risk, extended timelines, and unavoidable short-term earnings volatility. A private ownership structure, they contend, eliminates quarterly reporting pressures and enables deployment of long-term capital to pursue disciplined acquisitions and R&D initiatives without the constraints imposed by public market expectations.
Transaction completion is anticipated in the fourth quarter of 2026, contingent upon standard regulatory clearances and achievement of a minimum acceptance threshold of 66.67% of outstanding shares. The transaction structure and committed capital base suggest institutional confidence in the strategic logic underpinning Recordati's privatization and its rare disease-focused growth agenda.
CVC's involvement dates to 2018 and has grown substantially; the firm currently holds 46.8% of Recordati through its Rossini holding company and has irrevocably committed to tender its existing stake. Groupe Bruxelles Lambert is committing up to €1.3 billion to secure a co-control position, establishing itself as the transaction's co-lead alongside CVC. The consortium has secured commitments from institutional co-investors including the Abu Dhabi Investment Authority, Canada Pension Plan Investment Board, and Recordati's chairman Andrea Recordati, signaling broad institutional backing for the privatization.
The strategic rationale reflects a significant operational shift driven by Recordati's expansion trajectory. Since 2018, the company has completed sixteen acquisitions while building its rare disease platform—a competitive, capital-intensive segment requiring sustained research and development spending and access to early-stage assets. The sponsors argue that executing this strategy as a public company introduces execution risk, extended timelines, and unavoidable short-term earnings volatility. A private ownership structure, they contend, eliminates quarterly reporting pressures and enables deployment of long-term capital to pursue disciplined acquisitions and R&D initiatives without the constraints imposed by public market expectations.
Transaction completion is anticipated in the fourth quarter of 2026, contingent upon standard regulatory clearances and achievement of a minimum acceptance threshold of 66.67% of outstanding shares. The transaction structure and committed capital base suggest institutional confidence in the strategic logic underpinning Recordati's privatization and its rare disease-focused growth agenda.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.